HER2/ErbB2, an epidermal growth factor receptor-related tyrosine kinase, is overexpressed on the surface of a variety of tumors of epithelial origin, such as breast tumors, ovarian carcinomas, and gastric tumors, and therefore constitutes an ideal therapeutic target (1-3). Among the many advances in the development of HER2-targeted cancer therapy over the past decade (4 -7), antibody-based strategies (e.g. herceptin (trastuzumab) (8 -10), intracellular antibody (11, 12), and fusion proteins for targeted delivery of various classes of therapeutic agents (13-17)) are especially notable. Our previous studies exploited the in vitro and in vivo cytotoxicity of immunotoxins by generating a new class of antigen-specific killer cells (18, 19) , but this approach may well be limited in its clinical applications because of antigenicity of heterogeneous toxin protein. Hence, our attention turned to human endogenous proteins, especially those acting as executioners during apoptosis, which in principle should be optimal candidates for triggering the death of tumor cells in an intrinsic physiological manner.
HER2/ErbB2, an epidermal growth factor receptor-related tyrosine kinase, is overexpressed on the surface of a variety of tumors of epithelial origin, such as breast tumors, ovarian carcinomas, and gastric tumors, and therefore constitutes an ideal therapeutic target (1) (2) (3) . Among the many advances in the development of HER2-targeted cancer therapy over the past decade (4 -7), antibody-based strategies (e.g. herceptin (trastuzumab) (8 -10) , intracellular antibody (11, 12) , and fusion proteins for targeted delivery of various classes of therapeutic agents (13) (14) (15) (16) (17) ) are especially notable. Our previous studies exploited the in vitro and in vivo cytotoxicity of immunotoxins by generating a new class of antigen-specific killer cells (18, 19) , but this approach may well be limited in its clinical applications because of antigenicity of heterogeneous toxin protein. Hence, our attention turned to human endogenous proteins, especially those acting as executioners during apoptosis, which in principle should be optimal candidates for triggering the death of tumor cells in an intrinsic physiological manner.
Granzymes are a family of granular serine proteinases produced by cytotoxic T lymphocytes and natural killer cells, with a triad of key residues, histidine, aspartate, and serine, conserved at the catalytic site (20, 21) . One member of the family, granzyme B (GrB), 1 plays an essential role in granule-mediated killing. GrB is originally synthesized as zymogen and activated by removal of the amino-terminal signal peptide and an acidic dipeptide after lymphocyte receptor recognition (21) . The active GrB (GrBa) is then released from leukocyte granules by exocytosis, entering target cells to cause extensive proteolysis at specific amino acid residues (22, 23) . GrB-mediated apoptosis involves the caspase-dependent pathway, direct nuclear entry, and caspase-independent pathways (24 -28) . The potential of GrB therapy to induce multiple apoptotic pathways makes this approach to tumor cell killing especially attractive.
In our most recent previous study, chimeric immunocasp-3 protein was shown to have a potent selective antitumor effect both in vitro and in vivo (29) . This result led us to another targeted pro-apoptotic fusion protein, designated immunoGrB, which consisted of a single-chain anti-HER2 antibody, e23sFv (30, 31) , a Pseudomonas exotoxin A (PE) translocation domain (32) (33) (34) (35) , and active GrB (GrBa) (21) . The recombinant immunoGrB molecule was predicted to bind to tumor cells overexpressing HER2 and be internalized, such that endosomal cleavage would give rise to the active granzyme B domain that would consequently translocate into the cytosol to induce tumor cell death (18, 19, 29) . Here we evaluate the antitumor activity of immunoGrB and immunoGrB-secreting lymphocytes in both in vitro and in vivo models.
EXPERIMENTAL PROCEDURES
Construction of Expression Plasmids-The human GrB gene was obtained by reverse-transcription PCR from total RNA derived from healthy human peripheral blood mononuclear cells (PBMCs) following stimulation with 15 g ml Ϫ1 phytohemagglutinin (Sigma) for 72 h using a Superscript kit (Invitrogen). A mutant GrB (mGrB) gene, in which a serine codon of a catalytic triad coding sequence was replaced with a cysteine codon (S183C), was generated by two-step overlapping PCR (36) . GrBa (active GrB) and mGrBa (mutant active GrB) genes were * This work was supported by the National High Technology Research and Development Program of China Grant 2001AA217101 (to A.-G. Y.) and by the China National Science Fund for Distinguished Young Scholars Grant 39925036 (to A.-G. Y.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
ʈ To whom correspondence should be addressed. amplified by PCR and fused in-frame at the 5Ј-end with part of the PE domain II sequence encoding amino acids (aa) 280 -364 or aa 280 -358. The resulting PE II-GrBa fusion genes were cloned into pcDNA3 (Clontech), pIRES2-EGFP (Clontech), and pIND (Invitrogen), respectively. Then, the immunotoxin expression vector pCMV-e23sFv-PE40 (18) , in which a signal peptide-coding sequence was located upstream of the e23sFv-PE40 fusion gene, was used to generate the expression vector pCMV-e23sFv-PE II-GrBa (pCMV-immunoGrB). The fusion genes encoding PE domain II (aa 253-364 or aa 253-358) and GrBa (or mGrBa) were constructed by overlapping PCR and substituted for PE40 coding sequence in pCMV-e23sFv-PE40, yielding pCMV-immunoGrB. To generate the pLNCX-immunoGrB retroviral vector, we inserted the immunoGrB gene with the leader signal sequence into the pLNCX-e23sFv-PE40 vector (18) , with the cytomegalovirus promoter and the neomycin resistance gene. All constructed vectors were confirmed by DNA sequencing. The detailed procedure for construction of the vectors will be provided upon request.
Mammalian To obtain retrovirus carrying the immunoGrB gene, we transfected the pLNCX-immunoGrB retroviral vector into the PA317 amphotropic packaging cell line followed by 600 g ml Ϫ1 G418 selection over 2 weeks. The virus-containing supernatants were collected from confluent cell monolayers, passed through a 0.22-m pore size filter, and stored at Ϫ70°C. Titers were determined on mouse fibroblast cells NIH3T3 selected in G418 (500 g ml Ϫ1 ), and high producer clones (5 ϫ 10 4 colony-forming units ml Ϫ1 ) were chosen for additional study. Fortyeight hours after stimulation with 1 g ml Ϫ1 plate-bound anti-CD3 (Pharmingen) in medium supplemented with 20 units ml Ϫ1 interleukin 2 (IL-2) (Sigma) and 15 g ml Ϫ1 phytohemagglutinin (Sigma), PBMCs from healthy individuals were infected with retrovirus supernatant in the presence of Polybrene (8 g ml Ϫ1 , Sigma) by spin infection at 1000 ϫ g for 90 min. Then, the infected PBMCs were selected in 300 g ml Ϫ1 G418 for 1 week and expanded in the culture medium.
Immunocytochemical and Histological Analyses-Cells on coverslips were transfected with DNA and stained 72 h after transfection. The samples were fixed in 4% paraformaldehyde, permeabilized in PBS with 0.1% Triton X-100, blocked in 2% normal rabbit serum in PBS, and then incubated overnight at 4°C in a mixture of goat anti-GrB polyclonal antibody (Santa Cruz Biotechnology) at a 1:200 dilution and mouse anti-␣-tubulin monoclonal antibody (Molecular Probes) at a 1:100 dilution. Cells were extensively washed with PBS and incubated in biotin-labeled anti-goat secondary antibody (Sigma) at 1:100 dilution for 2 h at room temperature followed by further rinsing and incubation in a mixture of Cy3-conjugated avidin-biotin complex (Sigma) and fluorescein isothiocyanate-conjugated anti-mouse IgG (Sigma) at 1:100 dilution for 1 h at room temperature. Then, cells were washed and mounted on slides. For immunohistochemical staining, the paraffin sections were dewaxed, hydrated, and incubated in methanol-H 2 O 2 for 20 min to remove endogenous peroxidase. Tissue sections were then stained with the GrB antibody according to the immunohistochemical horseradish peroxidase-conjugated avidin-biotin complex procedure described above.
Cell Viability Assay-For the MTT assay, transfected HeLa cells were plated in 96-well dishes at a density of 5 ϫ 10 3 cells/well. The samples were triplicated and incubated for the indicated times. Aliquots of 20 l of 5 mg ml Ϫ1 MTT (Sigma) in PBS were added to each well, and the cells were incubated for another 4 h followed by the addition of 150 l of Me 2 SO. The A 490 values were assayed in a Sunrise microplate reader (Tecan, Groedig, Austria). Cells were placed into 24-well plates (3 ϫ 10 4 /well) and counted at the indicated times. Viable cells were identified by trypan blue exclusion, and the mean of three parallel samples was calculated.
Immunoprecipitation and Western Blotting-Following induction with ponasterone A (Invitrogen), transfected HeLa cells were lysed in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM MgCl 2 , 0.5% Nonidet P-40, and 1 mM phenylmethylsulfonyl fluoride. Lysates were clarified by centrifugation at 10,000 rpm for 10 min at 4°C. Recombinant PE II-GrBa proteins were immunoprecipitated by goat anti-GrB polyclonal antibody, and endogenous DFF45 proteins were immunoprecipitated by goat anti-DFF45 polyclonal antibody (Santa Cruz Biotechnology). Immune complexes were recovered with protein G-Sepharose beads (Invitrogen) and, after extensive washes, boiled from the beads and subjected to Western blotting. Samples were separated on 12% SDS-PAGE and transferred to polyvinylidene difluoride membrane (Amersham Biosciences). The membrane was incubated with goat anti-GrB or anti-DFF45 antibody followed by immunohistochemical horseradish peroxidase-conjugated avidin-biotin complex analysis. Detection was performed with ECL Western blotting detection reagents (Amersham Biosciences).
GrB Activity Assay-The following procedures were done on ice unless stated otherwise. The lysates of transfected HeLa cells were triplicated in 96-well plates. A stock solution of Ac-IETD-pNA (Calbiochem) in Me 2 SO, a synthetic peptide substrate of GrB, was used at a final concentration of 0.2 mM in the buffer (0.2 M HEPES, 0.3 M NaCl, 1 mM EDTA, 0.5% (v/v) Triton X-100, pH 7.0). After incubation for 5 min at 27°C, substrate hydrolysis was measured by colorimetric absorbance changes at 405 nm.
Cytotoxicity Assay in Vitro-Transwell filters (Costar), 12-mm diameter, 0.40-m pore size, which separate the cells but not large molecules, were used for cocultivation assay. Tumor cells overexpressing HER2 (SKBR-3 and SKOV-3) and control cells expressing undetectable HER2 (HeLa and ECV-304) were placed at the bottom chamber, and the transfected Jurkat cells were placed at the top chamber at different ratios. Viable cells at the bottom chambers were counted by trypan blue exclusion at the indicated times after cocultivation. The percentages of cell killing were determined as follows: (1 Ϫ the number of cells cocultured with Jurkat-immunoGrB/the number of cells cocultured with Jurkat controls) ϫ 100%.
In Vivo Antitumor Activity of ImmunoGrB-SKBR-3 tumor cells (1 ϫ 10 6 ) were injected subcutaneously into the right hind flank of athymic mice (4 -6 weeks old). When palpable tumors (normally 75-150 mm 3 ) arose within 16 -21 days, mice were randomized to treatment and control groups. Two groups of eight mice each were injected intramuscularly in the right hind limb with 10 g of LipofectAMINE-encapsulated pCMV-immunoGrB or empty pCMV vector every 3 days for 3 weeks. Two groups (five mice each) were intravenously administered pCMV-immunoGrB-transfected or pCMV-transfected Jurkat cells (5 ϫ 10 6 ) weekly for 3 weeks. Another two groups (six mice each) received weekly intravenous injections of 5 ϫ 10 6 immunoGrB-transduced or mock-transduced PBMCs for 3 weeks. Tumor growth was monitored by caliper-measuring two perpendicular tumor diameters every 3 days, and the volume of the tumor was calculated from the formula: tumor volume ϭ (width) 2 ϫ length/2 (37). Mice were sacrificed by cervical dislocation, and various tissues were removed to prepare paraffin sections for histological staining.
RESULTS

Ectopic Expression of GrBa Contributes to Effective Cell
Death-Extensive studies have shown that purified natural or recombinant GrB protein or GrB-expressing cytotoxic T lymphocytes will induce target cells to initiate an internal suicide program via the well characterized granule exocytosis mechanism (21) . The pro-apoptotic activity of GrBa in the absence of perforin was further demonstrated by microinjection of GrBa protein into the cytoplasm of MCF-7 cells (22) . To investigate whether the same cytotoxic effect could be achieved in mammalian cells by self-expressed GrBa protein in the cytoplasm, we transiently transfected HeLa cells with GrBa expression vectors. As shown in Fig. 1A , in contrast to the mock transfectants, transient expression of the GrBa gene led to apparent cell death at 12 h after transfection, and enhanced cell death was observed at a prolonged time. In addition, about 5% of the GrBa transfectants appeared as a volume extension, often with multiple nuclei (Fig.  1B) , which suggested some cytoskeletal changes caused by GrBa (27) . As assayed by immunofluorescent staining with an anti-␣-tubulin antibody, GrBa-expressing giant cells displayed abnormal cytoskeleton with evidence of leakage of nuclear materials into the cytoplasm as well as multiple spindle poles (Fig. 1B) . Abnormal mitotic poles indicated the arrest of normal mitosis (38) , which possibly contributed to the multilobed or multiple nuclei appearance of the giant cells. Moreover, the GrBa-transfected HeLa cells proliferated much slower than the non-transfectants and the mock transfectants (Fig. 1C) . We conclude that the ectopic expression of GrBa causes cell death via apoptosis induction and division inhibition.
Cytotoxicity of PE II-GrBa Fusion Proteins Similar to GrBa-The data presented above suggest that the introduction of an exogenous GrBa gene into tumor cells may result in cell death. The immunoGrB antitumor strategy requires activation of immunoGrB after binding and internalization to tumor cells. Such activation could be achieved by endosomal cleavage at Arg 279 of the PE translocation domain, releasing into the cytosol a carboxyl-terminal fragment, PE II-GrBa, containing part of PE domain II (aa 280 -364 or aa 280 -358) and GrBa (33, 35) . Thus, we constructed PE II-GrBa fusion protein genes in which a sequence encoding aa 280 -364 or aa 280 -358 of PE was included ( Fig. 2A) and investigated their effects on transfected cells.
Transient expression of PE II-GrBa fusion genes in HeLa cell line (Fig. 2B) and several other mammalian cell lines (data not shown) gave rise to impressive cell death, similar to that seen with GrBa. Electronic microscopy applied to PE II-GrBa transfectants demonstrated about 13% apoptotic cells (Fig. 2C, panel  1) , over 25% cells characteristic of secondary necrosis (Fig. 2C,  panel 2 ), and about 6% giant cells with multilobed or multiple nuclei (Fig. 2C, panel 3) . To exclude the possibility that the effects were due to overexpression of exogenous genes, we established HeLa cells inducibly expressing PE II-GrBa fusion proteins. The expression of PE II-GrBa resulted in the cleavage of endogenous DFF45, a substrate of GrBa (28), producing a 28-kDa proteolytic product, which is not found in the mutants in which catalytic Ser 183 was replaced with a cysteine (Fig. 2D) . Likewise, comparable 20 -30-fold increases of GrB activity on Ac-IETD-pNA were detected in HeLa-PE II-GrBa cells after ponasterone A induction but not in cells expressing the inactivated mutants (Fig. 2D) . In contrast to pIND-transfected and mutant-transfected cells, ponasterone A induction inhibited the growth of HeLa cells transfected with PE II-GrBa, and expression of the fusion protein containing PE aa 280 -358 caused stronger growth inhibition (Fig. 2E) . Cell cycle analysis demonstrated the decrease of G 2 phase cells (data not shown). These findings suggest that NH 2 -terminal PE-derived peptide does not abrogate the activity of GrBa; hence, the PE II-GrBa fusion proteins maintain a cytotoxic effect on the cells that express them.
Selective Killing of Tumor Cells Overexpressing HER2 by ImmunoGrB Gene-modified Jurkat Cells-To induce specific tumoricidal effects, we fused the gene of an anti-HER2 singlechain antibody (e23sFv) in-frame to the 5Ј-end of the fusion genes encoding PE domain II (aa 253-364 or aa 253-358) and GrBa or mGrBa, forming immunoGrB molecules with an NH 2 -terminal signal peptide sequence (18, 29) (Fig. 3A) . Tumorspecific killer cells were generated by transfecting pCMV-immunoGrB into a CD4 ϩ Jurkat cell line followed by G418 selection. The immunoGrB transcripts were identified in the G418-resistant cells by reverse transcription-PCR using a pair of primers that amplified the truncated PE II-GrBa fragments of about 500 bp, and the presence of the secreted immunoGrB proteins was confirmed in the culture medium by Western blotting (Fig. 3B) . The immunoGrB gene-modified Jurkat cells showed normal proliferation rates and viability as compared with parental Jurkat cells (data not shown).
We next evaluated the cytotoxicity of the immunoGrB-secreting lymphocytes toward tumor cells in vitro, first determining which of the immunoGrB molecules containing different PE II sequences exerted the more powerful killing activity. This assessment was made by cocultivating HER2-overexpressing SKBR-3 cells with various Jurkat-immunoGrB cell lines. As shown in Fig. 3C , Jurkat-e23sFv-PE II 253-358 -GrB killed the largest number of tumor cells, and its killing activity was enhanced by prolonged incubation, leading us to choose this line of modified cells for additional studies. To determine the specificity of cytotoxicity, the genetically altered Jurkat cells were cocultivated with SKBR-3 and SKOV-3 cells overexpressing HER2 or with HeLa and ECV-304 cells with undetectable HER2 expression (29) . Significant killing of both HER2-overexpressing cell lines by Jurkat-e23sFv-PE II 253-358 -GrB was observed, especially SKBR-3 cells, which express higher levels of HER2, whereas neither HeLa nor ECV-304 cells were killed by this cell line (Fig. 3C ). An increased ratio of Jurkat to target cells resulted in enhanced killing of cells overexpressing HER2 (Fig. 3C) . Thus, immunoGrB molecules secreted by lymphocytes are capable of recognizing and destroying HER2-overexpressing tumor cells but not normal cells or tumor cells lacking HER2 expression.
FIG. 1. Cell death caused by ectopic expression of GrBa.
A, HeLa cells were transfected with pIRES2-EGFP or pIRES2-EGFPGrBa and observed under a fluorescence microscope (Olympus BX-60) at the indicated times after transfection. Magnification was ϫ400. B, HeLa cells were transfected with pcDNA3-GrBa and subjected to immunofluorescent staining with a mixture of anti-␣-tubulin antibody/ fluorescein isothiocyanate (FITC) and anti-GrB antibody/Cy3 72 h after transfection, together with 4Ј,6-diamidino-2-phenylindole (DAPI) staining for nucleus. Cytoskeletal changes and multiple spindle poles are shown. Magnification was ϫ400. C, growth curves of non-transfected (E), pIRES2-EGFP-transfected (‚), and pIRES2-EGFP-GrBa-transfected (OE) HeLa cells were assessed by MTT assay with the mean data from two independent experiments, each carried out in triplicate.
Growth Inhibition of HER2-overexpressing Tumors in Nude
Mice-The in vivo antitumor activity of immunoGrB was also tested in nude mouse models. When palpable tumors arose in mice injected subcutaneously with SKBR-3 cells, the mice received seven doses of 10 g of LipofectAMINE-encapsulated pCMV-immunoGrB intramuscularly every 3 days in the right posterior limb or three weekly intravenous injections of 5 ϫ 10 6 Jurkat-immunoGrB or PBMCs-immunoGrB cells. As shown in Fig. 4A , injection with immunoGrB-expressing plasmid led to 53.7% inhibition of SKBR-3 tumor growth after a 3-week treatment, as compared with 63.3% inhibition in the mice injected with immunoGrB gene-modified Jurkat cells. The mice receiving intravenous injections of immunoGrB gene-transduced PBMCs survived longer than those intramuscularly injected with pCMV-immunoGrB (Fig. 4B ). This result indicated that although immunoGrB molecules could be produced and secreted in vivo by modified muscle cells (Fig. 4C) , the engineered lymphocytes exhibited higher antitumor activity presumably because of a sustained secretion of targeted killer protein and their diffusion through blood and lymph fluid. We next studied the in vivo distribution of immunoGrB in the mice that received genetically modified Jurkat cells. Immunohistochemical analysis with a GrB antibody demonstrated efficient local accumulation of immunoGrB molecules at a variety of tumor sites containing dying cells. There was neither detectable localization of immunoGrB nor histological abnormalities in the heart, liver, lung, or kidney (Fig. 4C) . The data presented above suggest that immunoGrB protein secreted by muscle cells or lymphocytes in vivo can effectively target and suppress tumors overexpressing HER2.
DISCUSSION
Granzyme B is generally believed to kill a cell via multiple apoptotic pathways in synergy with perforin. In the mannose 6-phosphate receptor pathway, perforin seems to play an important role in the delivery of granzyme B from the endocytic compartment to the cytosol, where granzyme B is accessible to its substrates (39) . Alternative means that allowed transport of granzyme B to the cytosol, such as application of an endosomedisrupting agent (40) and cytoplasmic microinjection of the granzyme B protein (22) , hardly abrogated the pro-apoptotic activity of granzyme B, raising the possibility that perforin is not necessarily required. Our immunoGrB strategy, in which a novel chimeric protein is generated by fusing an anti-HER2 single-chain antibody and a PE translocation domain sequentially to GrBa, provides such an approach to targeted cell killing that sidesteps perforin. In theory, the immunoGrB molecule can bind to and enter HER2-overexpressing tumor cells. Based on the well characterized translocation mechanism of PE domain II in chimeric toxins (33, 35) , autocleavage of the PE translocation domain between Arg 279 and Gly 280 in the target cell endosomes would give rise to a COOH-terminal fragment, PE II-GrBa, which comprises GrBa and the short PE-derived peptide beginning with Gly 280 . The resulting fragment would consequently translocate to the cytosol, exert GrBa-like activity, and induce the cell to undergo apoptosis. Factually, selective binding to HER2-overexpressing tumors and release of a cytotoxic domain to tumor cell cytosol, which is crucial for the desired antitumor behavior of immunoGrB, have been verified by our previous studies with related killer proteins (18, 19, 29) .
In this study, we have described the construction and func- 280 -364) inframe at the 5Ј end of the sequence of GrBa or its enzymatic mutant (S183C). B, HeLa cells were transiently transfected with pIRES2-EGFP, pIRES2-EGFP-PE II-GrBa, and pIRES2-EGFP-PE IImGrBa, respectively, and observed under a fluorescence microscope 72 h after transfection. Magnification was ϫ400. C, the pcDNA3-PE II-GrBa-transfected HeLa cells were observed under the electronic microscope (JEM-2000EX, JEOL Ltd., Tokyo, Japan). Nuclear chromatin condensation (1, ϫ6000), secondary necrosis (2, ϫ2000), and giant cells with multilobed or multiple nuclei (3, ϫ3000) are shown. D, HeLa cells were cotransfected with pIND-PE II-GrBa and an assistant plasmid, pVgRXR (Invitrogen) followed by 500 g ml Ϫ1 G418 and 800 g ml Ϫ1 zeocin selection. The lysates of the resistant cells on ponasterone A induction were subjected to immunoprecipitation and Western blotting with a GrB antibody (Ab) or a DFF45 antibody. The GrB activity of the lysates on synthetic peptide Ac-IETD-pNA was evaluated as the ratio of after induction to preinduction A 405 . E, after ponasterone A induction, viable HeLa cell transfectants of pIND (-E-), Jurkat-immunoGrB (-ࡗ-) and Jurkatcontrol (⅐⅐⅐ࡗ⅐⅐⅐) (five mice/group) or PBMCs-immunoGrB (-OE-) and PBMCs-control cells (⅐⅐⅐OE⅐⅐⅐) (six mice/group) weekly for 3 weeks. Tumor volume was monitored, and tumor growth curves (A) and mouse survival times (B) were determined. C, after intramuscular injection with pCMV-immunoGrB or intravenous injection with Jurkat-immunoGrB cells, tissues were subjected to immunohistochemical analysis with a GrB antibody. Magnification was ϫ400.
feres with the formation of GrBa catalytic center and because the membrane lipid bilayer bars access of the secreted molecule to the cytosol. Given that endocytosis of the immunoGrB protein by HER2-overexpressing tumor cells would result in the release of PE II-GrBa to the cytosol, we therefore investigated whether the PE-derived peptide affected the GrBa activity. The data from both transient and inducible expression showed that the PE II-GrBa was enzymatically active and effectively caused cell death, similar to that seen with GrBa transfectants. Interestingly, in addition to the expected apoptosis-inducing capacity, ectopic expression of GrBa in the cytosol also led to a minority of giant multinuclear cells due to mitotic and cytoskeletal abnormalities. One potential explanation for this is that the giant cells only express subtoxic levels of GrBa and therefore fail to produce lethal phenotypes immediately. Although these cells survive for the time being, the aberrant mitotic events are sufficient to kill them even in the absence of apoptosis (41) (42) (43) . Furthermore, in vitro and in vivo data demonstrated significant killing of HER2-overexpressing tumor cells, but not HER2-negative tumor cells or normal cells, by genetically modified Jurkat cells. In contrast to the immunotoxins that we generated previously (18, 19) , the immunoGrB molecule possesses only minor immunogenicity and therefore should be applicable to long term treatment of tumors that overexpress HER2. Moreover, unlike our immunocasp-3 construct (29) , immunoGrB would be especially useful when the caspase-dependent apoptotic pathway is not available in tumor cells (21, 44) .
Because of uncertainty as to whether the minimal fragment of PE is necessary for its translocation activity (32-35), we constructed immunoGrB proteins containing PE aa 253-364 or aa 253-358 and compared their antitumor effects in vitro. Importantly, the immunoGrB molecule that included PE aa 253-358 killed more tumor cells overexpressing HER2, and the PE II-GrBa construct that contained PE aa 280 -358 inhibited cell proliferation more strongly. This advantage may reflect a lesser influence of the shorter NH 2 -terminal PE-derived peptide on correct folding of the enzymatic center for GrBa activity and on the ability of the molecule to escape from endosomes.
A major concern in the development of HER2-targeted therapies is the expression of the target antigen on normal tissues (45) . Numerous studies with herceptin (trastuzumab), although demonstrating significant clinical benefits in patients with HER2-positive primary and metastatic breast cancer, have reported notable cardiotoxicity in a few patients, presumably because of interference with normal HER2 signaling in the heart (10). By contrast, immunoGrB fusion proteins are expected to be less toxic over repeated treatments because of enhanced antitumor activity by the addition of an apoptotic effector that permits decreased doses of the targeted killer protein to be used in vivo.
Given that almost any molecule can be targeted on the cell surface, chimeric killer proteins comprising a single-chain antibody and a human endogenous apoptotic molecule could be added to the growing repertoire of targeted therapies to increase the diversity of antigen recognition, thereby inducing redundant cell death. The development of additional ligandreceptor system and engineered antibodies will be needed to extend the application of targeted killer proteins to additional disease states (18) .
